Grovepoint buys control of Algatechnologies at $50m company value

The UK equity firm bought control of the Kibbutz Ketura start up, which cultivates microalgae to supply a powerful antioxidant.

British private equity firm Grovepoint Capital has acquired control of biotechnology company Algatechnologies Ltd. at a value of $50 million. Founded by Kibbutz Ketura in 1998, Algatechnologies commercially cultivates the microalgae Haematococcus pluvialis to supply a powerful antioxidant - astaxanthin.

Algatechnologies was founded on the basis of research by Prof. Sammy Boussiba at Ben Gurion University of the Negev Landau Family Microalgal Biotechnology Laboratory, and the company is run by chairman Ed Hofland and CEO Hagay Tzur. The company's shareholders are Kibbutz Ketura and the Jewish Colonization Association.

Algatechnologies' main product, AstaPure, is an antioxidant sold as a nutritional supplement and component in cosmetic formulas. Studies have found that antioxidants help prevent damage to cells in the skin, brain, and other organs. To date, no pharmaceuticals have been developed directly from antioxidants, nor have they undergone controlled large clinical trials, like the studies conducted on pharmaceuticals. Nonetheless, many academic studies report a link between antioxidants and general health.

Algatechnologies does not sell AstaPure directly to consumers, but to manufacturers which use it in their products. The company declines to disclose its sales, but market sources estimate them at tens of millions of dollars.

Grovepoint partner Brad Fried told "Globes", "The product can be produced because of the Arava's climatic conditions. That is why we will keep development and production in Israel even as we expand the company's international distribution network."

Grovepoint Israel partner Hagai Stadler told "Globes", "We will expand Algatechnologies' production in the Arava and its international marketing network, and build another plant for the production of more microalgae-based biological substances."

Stadler added, "Algatech is one of the most interesting companies in Israel. Very few companies in the world have succeeded in growing microalgae, especially microalgae that produce substances with global demand at commercial quantities and prices."

Grovepoint was founded two years ago with institutional and private funding. The firm is co-managed by Bradley Fried and Leon Blitz. Grovepoint Israel, founded a year ago and managed by Hagai Stadler and Gil Meirovbich, is now being officially launched. Grovepoint Israel is focused on technologies and solutions in the fields of agriculture, food , water, energy and cleantech. This is Grovepoint's first major investment in Israel.

Published by Globes [online], Israel business news - www.globes-online.com - on February 10, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Biolight jumps on strong Zacks recommendation

Zacks cites the company for its technology, products, and meeting its targets.

VBL Therapeutics raises $40m in revived Nasdaq IPO

After the fiasco of the failed IPO in August, the drug development company scaled down the offering.

Assuta Hospital Gov't plans taxing private hospitals

The tax is one of the recommendations of the Economic Arrangments bill.

Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס